The short version
- Why people research itHair follicle stem cell activation through lactate (mouse); no peer-reviewed human result found.
- What the evidence isNo peer-reviewed human trial of PP405 was found.
- What to watchBurning, weeping or crusting of the scalp.
How PP405 works
The mechanism is one of the best-supported new ideas in hair biology. Follicle stem cells prefer glycolysis and lactate; deleting lactate dehydrogenase blocked their activation and deleting the pyruvate carrier gene accelerated it, and topical MPC inhibitors induced the hair cycle (Flores 2017).
Stem cells that run on glycolysis and make lactate activate; deleting lactate dehydrogenase stopped activation, and deleting the mitochondrial pyruvate carrier (MPC1), which forces pyruvate to be turned into lactate instead of entering mitochondria, accelerated activation and the hair cycle. The same paper found small molecules that inhibit the MPC and topically induce the hair cycle. PP405 belongs to that drug class: a topical MPC inhibitor meant to push follicle stem cells from dormancy into growth through lactate, a different lever from androgen blockade (finasteride) or potassium channel opening (minoxidil).
- Topical
On the goal map: Hair — follicle biology & the androgen problem (Skin, hair & aesthetics)
Research on PP4054 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Mechanistic and animal (mouse topical studies of the MPC-inhibitor class); no peer-reviewed human result for PP405 itself located.
Human clinical evidence
No peer-reviewed human trial of PP405 was found. No human efficacy or safety paper for a compound by this code was in PubMed as of 10 Nov 2026, so any human claim for it is an industry statement, not a published result. What would settle it is simple and measurable: a randomized, vehicle-controlled trial reporting target-area hair counts and local tolerability. The same applies to the vendor's liquid, which is not shown to be any developer's material.
Correlative data
No practice record. There is no case series or registry for topical MPC inhibitors in people outside industry programs.
How the mechanism reads
The mechanism is one of the best-supported new ideas in hair biology. Follicle stem cells prefer glycolysis and lactate; deleting lactate dehydrogenase blocked their activation and deleting the pyruvate carrier gene accelerated it, and topical MPC inhibitors induced the hair cycle (Flores 2017). Follow-up chemistry produced more than ten analogs that promoted hair growth in shaved mice (Liu 2021) and a separate 2026 series gave a lead that outperformed the tool compound, with no skin irritation in mice (Zhang 2026).
Experimental, animal or cellThe predicted downside is local. A drug that blocks pyruvate entry into mitochondria acts on every cell that absorbs it; with topical use systemic exposure should be low, but irritation, uneven growth and an unknown response in inflamed scalps are the sensible things to watch. Cancer biology also uses lactate heavily, which is a reason this class has to earn its safety data, not a reported finding.
Mechanistic
PP405 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Broken, inflamed or infected scalp skin, where a topical will absorb more than intended.
- Pregnancy or breastfeeding, since a drug that blocks pyruvate entry into mitochondria has no safety data there.
- A personal history of skin cancer on the treated area.
- Using it alongside other strong topicals without a gap, which confounds both irritation and results.
What’s expected
- Mild scalp dryness or tingling is the usual effect of a topical vehicle.
- No change for months: follicle cycles are slow, and early shedding is not evidence either way.
Watch for
- Burning, weeping or crusting of the scalp.
- Patchy growth or new patches of loss.
- Any systemic symptom such as dizziness, which would suggest unexpected absorption.
Labs that tell you it’s working
- Ferritin: iron deficiency is a common reversible cause of shedding that has to be excluded first.
- Thyroid-stimulating hormone: thyroid disease mimics hair loss.
- Vitamin D: low levels are associated with shedding.
- Zinc: a deficiency can look the same.
Topical MPC inhibitor class with mouse evidence only; the vendor product has no published identity data, so the main risks are the unknown and local skin reaction. PMID 28812580 PMID 33534563 PMID 42235286
Bloodwork to runHow you would know it is working: 6 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
PP405 FAQ4 common questions
- Is PP405 approved for human use?
- No. PP405 is a research compound.
- What is PP405 researched for?
- Hair follicle stem cell activation through lactate (mouse); no peer-reviewed human result found.
- Which labs show whether it's doing anything?
- Ferritin; Thyroid-stimulating hormone; Vitamin D; Zinc: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for PP405: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



